Novel phytopeptide osmotin mimics preventive effects of adiponectin on vascular inflammation and atherosclerosis

Examining the Potential of Developing and Implementing Use of Adiponectin-Targeted Therapeutics for Metabolic and Cardiovascular Diseases

“…Functional analyses revealed similar biological effects, evaluated as the induction of IL-6 production in synovial fibroblasts, of fAd (5 ug/ml) and osmotin peptide (5 ug/ml) (181,182). Studies with in-vivo, in-vitro treatment of osmotin also revealed its adiponectin's memetic effect toward obesity, diabetes and related fatty liver, cardiovascular diseases (183)(184)(185)(186). The activation of AdipoRs mediated downstream signaling pathways including AdipoRs/PPARα (185) and AdipoR1/PI3K/AKT (183) upon osmotin treatment, further confirmed the agonist activity of osmotin peptide to AdipoRs, in particularly to AdipoR1 (187).…”

IL-6-targeted ultrasmall superparamagnetic iron oxide nanoparticles for optimized MRI detection of atherosclerotic vulnerable plaques in rabbits

“…To perform the uptake experiments, 1 Â 10 5 RAW264.7 macrophages were preincubated with DMEM containing 10% FBS with LPS (1 mg mL À1 ) or without LPS for 24 h in 3.5 cm culture dish at 37 C with 5% CO 2 . Studies reported that RAW264.7 macrophages can be stimulated to overexpress IL-6 by LPS, 34,35 which immunouorescence staining was performed for verication. RAW264.7 cells cultured with or without LPS were xed in 4% paraformaldehyde and permeabilized with 0.5% Triton X-100 for 20 min.…”

Therapeutic properties of the new phytochemical osmotin for preventing atherosclerosis

“…Several studies have investigated preventive effects of plants on atherogenesis [4][5][6][7][8][9] . Osmotin, a plant-derived natural protein, is receiving the most attention as a therapeutic target for atherosclerosis and myocardial ischemia-reperfusion injury [10,11] .…”

“…Osmotin exhibits anti-inflammatory and anti-apoptotic effects in mammalian cells through AdipoR1 [24,25] . Takahashi et al [10] recently showed that osmotin exerts atheroprotective effects through human AdipoR1 in human vascular cells. In intracellular signaling pathways, both nuclear factor-κB (NF-κB) and extracellular signal-regulated protein kinase 1/2 (ERK1/2) suppression and AMP-activated protein kinase (AMPK) activation play a pivotal role in the preventive effects of osmotin on inflammation and atherosclerosis [10] .…”

“…Osmotin as well as adiponectin binds to AdipoR1, leading to the activation of adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1 (APPL1) followed by phosphoinositide 3-kinase (PI3K)/Akt, AMPK, peroxisome proliferator-activated receptor-α (PPAR-α), and protein-tyrosine phosphatase 1B (PTP1B) [10] . The PTP1B activation suppresses RAF1 and ERK1/2 phosphorylation [10] . The activation of PI3K/Akt and/or AMPK suppresses apoptosis of vascular cells (ECs, VSMCs, and macrophages) and cardiomyocytes.…”